On October 14, 2024,  the Individualized Medicine Seminar and the 4th Health Innovation and Transformation Management Forum jointly organized by Central South University, National Engineering Research Center for Individualized Diagnosis and Treatment Technology, Furong Laboratory and other institutions, ended in Hainan.The conference gathered more than 400 participants from experts and scholars from all over the country, relevant government departments, universities in the field of healthcare, research institutes, hospitals, and representatives of healthcare big data-related industries. Healtech was invited to participate in the conference and was awarded the title of "High-Quality Medical Device R&D Service Provider for 2024".

High-Quality Medical Device R&D Service Provider for 2024

Beijing Healtech Pharmaceutical Technology Co.，Ltd was awarded as  "High-Quality Medical Device R&D Service Provider" .  Ms. Yan Jiangwei, Deputy General Manager of the company, attended the conference and participated in the announcement ceremony of the award list.

Solicitation and Selection of "High-Quality Medical Innovation and Transformation Service Providers"
The solicitation and selection of "High-Quality Medical Innovation and Transformation Service Providers for 2024" was conducted by the National Engineering Research Center for Individualized Diagnosis and Treatment Technology and Furong Laboratory, in cooperation with the Western Sichuan Medical Technology Transfer Center, China Technology Exchange, and Peking University Medical Science and Technology Innovation Center. The aim was to implement the national spirit of promoting industrialization in the health field, focus on serving the country's major medical strategies, concentrate on clinical technological innovation and domestic substitution in the health sector, cultivate and expand the ranks of medical innovation service enterprises, leverage the crucial catalytic role of third-party institutions in medical innovation and transformation, facilitate deep integration of the innovation chain, industry chain, and service chain, and advance the high-quality development of fruition conversions by research hospitals, medical colleges and universities, medical research institutions, and startup medical product companies.

The expert panel included strategic scientists and national-level talents in the medical field, heads of technology transfer from renowned hospitals and medical colleges, relevant heads of leading investment institutions, heads of relevant authoritative industry associations, and representatives from the National Engineering Research Center for Individualized Diagnostic and Therapeutic Technologies.

Conclusion
Healtech's inclusion in the list of "High-Quality Medical Device R&D Service Providers for 2024" is a testament to the group's integrated CRO&CDMO services. In the future, Autekon will collaborate with all parties to advance the high-quality fruition conversion of clinical products and continue to contribute to the development of the biomedical industry.